Synthesis and anti-Helicobacter pylori activity of pyloricidin derivatives -: I.: Structure-activity relationships on the terminal peptidic moiety

被引:16
作者
Hasuoka, A
Nishikimi, Y
Nakayama, Y
Kamiyama, K
Nakao, M
Miyagawa, KI
Nishimura, O
Fujino, M
机构
[1] Takeda Chem Ind Ltd, Div Pharmaceut Res, Med Chem Res Labs 1, Yodogawa Ku, Osaka 5328686, Japan
[2] Takeda Chem Ind Ltd, Mkt Div, Vaccine Grp, Chuo Ku, Osaka 5408645, Japan
[3] Takeda Chem Ind Ltd, Div Pharmaceut Res, Pharmaceut Discovery Ctr, Yodogawa Ku, Osaka 5328686, Japan
[4] Takeda Chem Ind Ltd, Div Pharmaceut Res, Tsukuba, Ibaraki 3004293, Japan
关键词
D O I
10.7164/antibiotics.55.322
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The novel natural antibiotics pyloricidin A, B and C possess potent and highly selective antibacterial activity against Helicobacter pylori. In order to investigate the structure activity relationships for the terminal peptidic moiety, a series of pyloricidin B and pyloricidin C derivatives, bearing various amino acids in the moiety, were prepared and evaluated for their anti-H. pylori activity. The derivatives bearing alpha-D-, beta- and gamma-amino acids or peptidemimetics showed drastically decreased activity. On the other hand, the derivatives with alpha-L-amino acids were found to maintain the activity. Among the derivatives prepared in this work, the allylglycine derivative 2s showed the most potent anti-H. pylori activity, with an MIC value of less than 0.006 mug/ml against H. pylori NCTC11637, which is 60-fold greater than the activity of the lead compound pyloricidin C.
引用
收藏
页码:322 / 336
页数:15
相关论文
共 16 条
[1]   DOUBLE-BLIND TRIAL OF OMEPRAZOLE AND AMOXICILLIN TO CURE HELICOBACTER-PYLORI INFECTION IN PATIENTS WITH DUODENAL-ULCERS [J].
BAYERDORFFER, E ;
MIEHLKE, S ;
MANNES, GA ;
SOMMER, A ;
HOCHTER, W ;
WEINGART, J ;
HELDWEIN, W ;
KLANN, H ;
SIMON, T ;
SCHMITT, W ;
BASTLEIN, E ;
EIMILLER, A ;
HATZ, R ;
LEHN, N ;
DIRSCHEDL, P ;
STOLTE, M .
GASTROENTEROLOGY, 1995, 108 (05) :1412-1417
[2]   SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI [J].
BAZZOLI, F ;
ZAGARI, RM ;
FOSSI, S ;
POZZATO, P ;
ALAMPI, G ;
SIMONI, P ;
SOTTILI, S ;
RODA, A ;
RODA, E .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) :773-777
[3]  
BELL GD, 1995, ALIMENT PHARM THERAP, V9, P41
[4]  
FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676
[5]  
FUJINO M, 1974, CHEM PHARM BULL, V22, P1857
[6]   TREATMENT OF PEPTIC-ULCERS CAUSED BY HELICOBACTER-PYLORI [J].
GRAHAM, DY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (05) :349-350
[7]   FACTORS INFLUENCING THE ERADICATION OF HELICOBACTER-PYLORI WITH TRIPLE THERAPY [J].
GRAHAM, DY ;
LEW, GM ;
MALATY, HM ;
EVANS, DG ;
EVANS, DJ ;
KLEIN, PD ;
ALPERT, LC ;
GENTA, RM .
GASTROENTEROLOGY, 1992, 102 (02) :493-496
[8]   SIMPLE SYNTHESIS OF L-VINYLGLYCINE AND D-VINYLGLYCINE (2-AMINOBUT-3-ENOIC ACID) AND RELATED AMINO-ACIDS [J].
HALLINAN, KO ;
CROUT, DHG ;
ERRINGTON, W .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1994, (24) :3537-3543
[9]   Total synthesis of novel antibiotics pyloricidin A, B and C and their application in the study of pyloricidin derivatives [J].
Hasuoka, A ;
Nishikimi, Y ;
Nakayama, Y ;
Kamiyama, K ;
Nakao, M ;
Miyagawa, K ;
Nishimura, O ;
Fujino, M .
JOURNAL OF ANTIBIOTICS, 2002, 55 (02) :191-203
[10]  
Janda K.D., 1997, Patent, Patent No. 9735199